Literature DB >> 2093628

Selection of healthy volunteers for phase I studies.

M Sibille1.   

Abstract

Healthy volunteers selection is one of the foundations for phase I results. Safety for volunteers, quality of data and reliability for study results depend on healthy volunteers selection. The selection aim is not to choose normal subjects but to exclude every people with diseases or risk factors which could result in increased danger for themselves or confuse the interpretation of study results. The selection procedure needs to define a list of relevant disease to be excluded depending on phase I objectives (tolerability, pharmacokinetic, pharmacodynamic). The choice of diseases is based on frequency, potential risk for the subjects or for the study. The selection is mainly a clinical process but because of asymptomatic diseases a laboratory screening is necessary and useful. This laboratory screening requires that a basic common list of relevant tests be determined and an appropriate method of cut-off point determination based on an evaluation of the risk of disease. According to the drug or the objective of the study adaptation of the procedure must be carried out. The percentage of erroneous inclusion of subjects is the best validation criterion for selection. The use of such a selection methodology by the author's group in Lyon results in a 50% exclusion for 494 first seen subjects with only 1% erroneous inclusion and 6% exclusion for laboratory test anomalies.

Entities:  

Mesh:

Year:  1990        PMID: 2093628     DOI: 10.1111/j.1472-8206.1990.tb00075.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  5 in total

1.  Adverse events in phase one studies: a study in 430 healthy volunteers.

Authors:  M Sibille; N Deigat; V Olagnier; D V Durand; R Levrat
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Upper limit of plasma alanine amino transferase during phase I studies.

Authors:  M Sibille; L G Lassonery; A Janin; N Deigat; B Boutouyrie; D V Durand
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Data driven evaluation of healthy volunteer characteristics at screening for phase I clinical trials to inform on study design and optimize screening processes.

Authors:  Annemie Deiteren; Erwin Coenen; Sabine Lenders; Peter Verwilst; Erik Mannaert; Freya Rasschaert
Journal:  Clin Transl Sci       Date:  2021-08-11       Impact factor: 4.689

4.  Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial.

Authors:  Susanne H Hodgson; Poppy Iveson; Jessica Larwood; Sophie Roche; Hazel Morrison; Catherine Cosgrove; Eva Galiza; Sabina Ikram; Nana-Marie Lemm; Savviz Mehdipour; Daniel Owens; Mihaela Pacurar; Michael Schumacher; Robert H Shaw; Saul N Faust; Paul T Heath; Andrew J Pollard; Katherine R W Emary; Katrina M Pollock; Rajeka Lazarus
Journal:  Clin Transl Sci       Date:  2021-10-20       Impact factor: 4.438

5.  Incidental diagnosis in healthy clinical trial subjects.

Authors:  Christopher J A Duncan; Rosalind Rowland; Patrick J Lillie; Joel Meyer; Susanne H Sheehy; Geraldine A O'Hara; Matthew Hamill; Hannah Donaldson; Laura Dinsmore; Ian D Poulton; Sarah C Gilbert; Helen McShane; Adrian V S Hill
Journal:  Clin Transl Sci       Date:  2012-03-06       Impact factor: 4.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.